Price T Rowe Associates Inc Aptevo Therapeutics Inc. Transaction History

Price T Rowe Associates Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$6.48 - $17.49 $299,376 - $808,037	46,200 New	46,200 $364,000
Q1 2021 May 17, 2021	SELL	$27.86 - $40.59 $175,518 - $255,717	-6,300 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$6.21 - $48.36 $39,123 - $304,668	6,300 New	6,300 $231,000

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $24.2M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.